Methods

US10322134B2 · kind B2 · utility

Assignee

• INTRA-CELLULAR THERAPIES, INC. · US

Inventors

• Kimberly VANOVER · New York, US
• Peng Li · New York, US
• Sharon Mates · New York, US
• Robert E. Davis · San Diego, US
• Lawrence P. Wennogle · Fryeburg, US

Key dates

• Filing date: Mar 12, 2018
• Grant date: Jun 18, 2019
• Expiry date: Mar 12, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.